FP10 Dysregulated aryl hydrocarbon receptor expression in keratinocytes and immune cells in atopic dermatitis influences its homeostatic and anti-inflammatory effects
Clicks: 1
ID: 318482
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #273 of 300 articles by views in the british journal of dermatology
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 300 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Introduction and aims The ligand-activated transcription factor aryl hydrocarbon receptor (AhR) has anti-inflammatory and skin barrier promoting functions, which have been harnessed for the treatment of atopic dermatitis (AD) with the recent US Food and Drug Administration approval of the topical AhR ligand Tapinarof. AhR activation induces CYP1A1 expression, which metabolizes physiological AhR ligands providing a negative feedback loop. We and others have shown that the AhR pathway is dysregulated in AD, with increased AHR expression, but reduced activation, potentially caused by excessive ligand metabolism. Here, we investigate this hypothesis and further dissect AhR expression in AD. Methods Skin biopsies from patients with AD not receiving systemic treatment (n = 15) and age/sex-at-birth/site-matched healthy volunteers (n = 17) were used to assess: (i) spatial epidermal AhR expression by RNAscope, and (ii) CYP1 enzymatic activity in healthy and AD epidermis by ethoxyresorufin-O-deethylase assay. Publicly available single-cell RNA sequencing (scRNAseq) datasets from AD and healthy skin and blood were analysed to further investigate AHR expression. Results The expression pattern of AHR differs in AD vs. healthy epidermis. AHR expression is widespread throughout healthy epidermis (n = 7), whereas it localizes mostly in basal keratinocytes in AD (n = 5), which was confirmed with scRNAseq. In blood, CD1C+CLEC10A+CLEC9A+ dendritic cells, CD14+ monocytes, and CCR4+PTGDR2+IL18R1+ T helper 2 cells express the highest level of AHR, which is increased in AD vs. healthy epidermis. Finally, CYP1 enzymatic activity shows no difference (P > 0.05) in basal or inducible activity in AD (n = 10) vs. healthy epidermis (n = 10). Conclusions We have identified a dysregulated AHR expression within AD epidermis, with increased AHR in AD basal keratinocytes vs. healthy epidermis, and declining expression in suprabasal AD keratinocytes. CYP1 enzyme activity is normal in AD, and thus not responsible for the previously identified reduced pathway activation. Further work investigating other checkpoints of the pathway, including AhR ligand availability, will provide a full assessment of the pathway to maximize its potential as a therapeutic target in AD.
| Reference Key |
openalex_W7165626057
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Hannah Dawe, Isabella Tosi, Katherine Teather, Mano Nakamura, Ineta Andrijauskaite, Jonathan Barker, C. Smith, Paola Di Meglio |
| Journal | the british journal of dermatology |
| Year | 2026 |
| DOI |
10.1093/bjd/ljag151.033
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.